Grand Pharmaceutical Group Limited (HKG: 0512)
Hong Kong
· Delayed Price · Currency is HKD 4.600
0.00 (0.00%)
Jan 3, 2025, 4:08 PM HKT
Grand Pharmaceutical Group Revenue
Grand Pharmaceutical Group had revenue of 6.05B HKD in the half year ending June 30, 2024, with 16.01% growth. This brings the company's revenue in the last twelve months to 10.59B, up 2.40% year-over-year. In the year 2023, Grand Pharmaceutical Group had annual revenue of 10.53B with 10.12% growth.
Revenue (ttm)
10.59B
Revenue Growth
+2.40%
P/S Ratio
1.52
Revenue / Employee
982.58K
Employees
10,534
Market Cap
16.11B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 10.53B | 967.31M | 10.12% |
| Dec 31, 2022 | 9.56B | 964.31M | 11.22% |
| Dec 31, 2021 | 8.60B | 2.25B | 35.34% |
| Dec 31, 2020 | 6.35B | -237.72M | -3.61% |
| Dec 31, 2019 | 6.59B | 632.28M | 10.61% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| BeiGene | 26.04B |
| Hansoh Pharmaceutical Group Company | 13.00B |
| JD Health International | 58.84B |
| WuXi Biologics | 18.39B |
| Sinopharm Group | 634.32B |
| Innovent Biologics | 8.01B |
| Sino Biopharmaceutical | 29.86B |
| CSPC Pharmaceutical Group | 33.53B |